BENZALKONIUM CHLORIDE 0.13% and THERAPEUTIC PRODUCT EFFECT INCOMPLETE

Overview

THERAPEUTIC PRODUCT EFFECT INCOMPLETE is the #17 most commonly reported adverse reaction for BENZALKONIUM CHLORIDE 0.13%, manufactured by Meijer, Inc.. There are 98 FDA adverse event reports linking BENZALKONIUM CHLORIDE 0.13% to THERAPEUTIC PRODUCT EFFECT INCOMPLETE. This represents approximately 2.9% of all 3,369 adverse event reports for this drug.

Patients taking BENZALKONIUM CHLORIDE 0.13% who experience therapeutic product effect incomplete should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

THERAPEUTIC PRODUCT EFFECT INCOMPLETE is a less commonly reported adverse event for BENZALKONIUM CHLORIDE 0.13%, but still significant enough to appear in the safety profile.

Other Side Effects of BENZALKONIUM CHLORIDE 0.13%

In addition to therapeutic product effect incomplete, the following adverse reactions have been reported for BENZALKONIUM CHLORIDE 0.13%:

• DRUG INEFFECTIVE — 124 reports
• DRUG HYPERSENSITIVITY — 116 reports
• CONDITION AGGRAVATED — 112 reports
• ARTHRALGIA — 110 reports
• THERAPY NON RESPONDER — 110 reports
• MUSCULOSKELETAL STIFFNESS — 108 reports
• PAIN IN EXTREMITY — 108 reports
• INFECTION — 107 reports
• HEPATOTOXICITY — 105 reports
• JOINT SWELLING — 105 reports

Other Drugs Associated with THERAPEUTIC PRODUCT EFFECT INCOMPLETE

The following drugs have also been linked to therapeutic product effect incomplete in FDA adverse event reports:

Does BENZALKONIUM CHLORIDE 0.13% cause THERAPEUTIC PRODUCT EFFECT INCOMPLETE?

THERAPEUTIC PRODUCT EFFECT INCOMPLETE has been reported as an adverse event in 98 FDA reports for BENZALKONIUM CHLORIDE 0.13%. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is THERAPEUTIC PRODUCT EFFECT INCOMPLETE with BENZALKONIUM CHLORIDE 0.13%?

THERAPEUTIC PRODUCT EFFECT INCOMPLETE accounts for approximately 2.9% of all adverse event reports for BENZALKONIUM CHLORIDE 0.13%, making it a notable side effect.

What should I do if I experience THERAPEUTIC PRODUCT EFFECT INCOMPLETE while taking BENZALKONIUM CHLORIDE 0.13%?

If you experience therapeutic product effect incomplete while taking BENZALKONIUM CHLORIDE 0.13%, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages